Scottish Medicines Consortium
Providing advice about the status of all newly licensed medicines
www.scottishmedicines.org.uk
Delta House 50 West Nile Street Glasgow G1 2NP Tel 0141 225 6999 Chairman: Professor Angela Timoney FRPharmS
NHS SCOTLAND

Product Update

pregabalin oral solution (Lyrica®) **(No:765/12)**

Pfizer Ltd

10 February 2012 *(Issued May 2012)*

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

pregabalin oral solution (Lyrica®) is accepted for restricted use in NHS Scotland

Indication under review: for the treatment of peripheral and central neuropathic pain in adults, as adjunctive therapy in adults with partial seizures with or without secondary generalization and the treatment of Generalised Anxiety Disorder (GAD) in adults.

SMC restriction: pregabalin oral solution should be prescribed only for patients who find it difficult to or are unable to swallow tablets.

The following SMC restrictions to the use of pregabalin apply:

- Pregabalin is restricted to use in patients with peripheral neuropathic pain who have not achieved adequate pain relief from, or have not tolerated, conventional first and second line treatments for peripheral neuropathic pain. Treatment should be stopped if the patient has not shown sufficient benefit within 8 weeks of reaching the maximally tolerated therapeutic dose.
- Pregabalin is restricted to use as adjunctive therapy in adults with partial seizures with or without secondary generalisation. It should be initiated only by physicians who have appropriate experience in the treatment of epilepsy and should be used principally in patients who have not benefited from treatment with an older anti-convulsant drug such as carbamazepine or sodium valproate, or for whom these drugs are unsuitable because of contra-indications, interaction or poor tolerance.

Pregabalin is not recommended for use in the treatment of Generalised Anxiety Disorder in adults as the company have not made a submission to SMC for use in this indication.

Pregabalin oral solution has been shown to be bioequivalent to pregabalin capsules.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 06 December 2011.

Chairman
Scottish Medicines Consortium